Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria Vaccine

Overview

Journal N Engl J Med

Specialty General Medicine

Date 2015 Oct 22

PMID 26488565

Citations 213

Authors

D E Neafsey

M Juraska

T Bedford

D Benkeser

C Valim

A Griggs

M Lievens

S Abdulla

S Adjei

T Agbenyega

S T Agnandji

P Aide

S Anderson

D Ansong

J J Aponte

K P Asante

P Bejon

A J Birkett

M Bruls

K M Connolly

U DAlessandro

C Dobano

S Gesase

B Greenwood

J Grimsby

H Tinto

M J Hamel

I Hoffman

P Kamthunzi

S Kariuki

P G Kremsner

A Leach

B Lell

N J Lennon

J Lusingu

K Marsh

F Martinson

J T Molel

E L Moss

P Njuguna

C F Ockenhouse

B Ragama Ogutu

W Otieno

L Otieno

K Otieno

S Owusu-Agyei

D J Park

K Pelle

D Robbins

C Russ

E M Ryan

J Sacarlal

B Sogoloff

H Sorgho

M Tanner

T Theander

I Valea

S K Volkman

Q Yu

D Lapierre

B W Birren

P B Gilbert

D F Wirth

Affiliations

Soon will be listed here.

Abstract

Background: The RTS,S/AS01 vaccine targets the circumsporozoite protein of Plasmodium falciparum and has partial protective efficacy against clinical and severe malaria disease in infants and children. We investigated whether the vaccine efficacy was specific to certain parasite genotypes at the circumsporozoite protein locus.

Methods: We used polymerase chain reaction-based next-generation sequencing of DNA extracted from samples from 4985 participants to survey circumsporozoite protein polymorphisms. We evaluated the effect that polymorphic positions and haplotypic regions within the circumsporozoite protein had on vaccine efficacy against first episodes of clinical malaria within 1 year after vaccination.

Results: In the per-protocol group of 4577 RTS,S/AS01-vaccinated participants and 2335 control-vaccinated participants who were 5 to 17 months of age, the 1-year cumulative vaccine efficacy was 50.3% (95% confidence interval [CI], 34.6 to 62.3) against clinical malaria in which parasites matched the vaccine in the entire circumsporozoite protein C-terminal (139 infections), as compared with 33.4% (95% CI, 29.3 to 37.2) against mismatched malaria (1951 infections) (P=0.04 for differential vaccine efficacy). The vaccine efficacy based on the hazard ratio was 62.7% (95% CI, 51.6 to 71.3) against matched infections versus 54.2% (95% CI, 49.9 to 58.1) against mismatched infections (P=0.06). In the group of infants 6 to 12 weeks of age, there was no evidence of differential allele-specific vaccine efficacy.

Conclusions: These results suggest that among children 5 to 17 months of age, the RTS,S vaccine has greater activity against malaria parasites with the matched circumsporozoite protein allele than against mismatched malaria. The overall vaccine efficacy in this age category will depend on the proportion of matched alleles in the local parasite population; in this trial, less than 10% of parasites had matched alleles. (Funded by the National Institutes of Health and others.).

Citing Articles

Estimation and Hypothesis Testing of Strain-Specific Vaccine Efficacy With Missing Strain Types With Application to a COVID-19 Vaccine Trial.

Heng F, Sun Y, Li L, B Gilbert P Stat Med. 2025; 44(6):e10345.

PMID: 40072429 PMC: 11906172. DOI: 10.1002/sim.10345.

Aqueous extract of Enantia chlorantha Oliv. demonstrates antimalarial activity and improves redox imbalance and biochemical alterations in mice.

Evbuomwan I, Adeyemi O, Oluba O BMC Complement Med Ther. 2025; 25(1):73.

PMID: 39994639 PMC: 11849376. DOI: 10.1186/s12906-025-04745-w.

Liver stage P. falciparum antigens highly targeted by CD4+ T cells in malaria-exposed Ugandan children.

Acevedo G, Samiee S, Ilala M, Levan J, Olive M, Hunter R PLoS Pathog. 2025; 21(2):e1012943.

PMID: 39993000 PMC: 11906071. DOI: 10.1371/journal.ppat.1012943.

Heterogeneous constraint and adaptation across the malaria parasite life cycle.

Perkins S, Neafsey D, Early A bioRxiv. 2025; .

PMID: 39990389 PMC: 11844417. DOI: 10.1101/2025.02.11.636054.

Distinguishing new from persistent infections at the strain level using longitudinal genotyping data.

Nickols W, Schwabl P, Niangaly A, Murphy S, Crompton P, Neafsey D bioRxiv. 2025; .

PMID: 39975299 PMC: 11839113. DOI: 10.1101/2025.02.06.636982.

References

Gilbert P . Comparison of competing risks failure time methods and time-independent methods for assessing strain variations in vaccine protection. Stat Med. 2000; 19(22):3065-86. DOI: 10.1002/1097-0258(20001130)19:22<3065::aid-sim600>3.0.co;2-d. View

Agnandji S, Lell B, Fernandes J, Abossolo B, Methogo B, Lumeka Kabwende A . A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N Engl J Med. 2012; 367(24):2284-95. PMC: 10915853. DOI: 10.1056/NEJMoa1208394. View

Good M, Pombo D, Quakyi I, Riley E, Houghten R, Menon A . Human T-cell recognition of the circumsporozoite protein of Plasmodium falciparum: immunodominant T-cell domains map to the polymorphic regions of the molecule. Proc Natl Acad Sci U S A. 1988; 85(4):1199-203. PMC: 279734. DOI: 10.1073/pnas.85.4.1199. View

Follmann D, Proschan M, Leifer E . Multiple outputation: inference for complex clustered data by averaging analyses from independent data. Biometrics. 2003; 59(2):420-9. DOI: 10.1111/1541-0420.00049. View

Kester K, Cummings J, Ofori-Anyinam O, Ockenhouse C, Krzych U, Moris P . Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. J Infect Dis. 2009; 200(3):337-46. DOI: 10.1086/600120. View

Agnandji S, Lell B, Soulanoudjingar S, Fernandes J, Abossolo B, Conzelmann C . First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N Engl J Med. 2011; 365(20):1863-75. DOI: 10.1056/NEJMoa1102287. View

Hall B, Fauci A . Malaria control, elimination, and eradication: the role of the evolving biomedical research agenda. J Infect Dis. 2009; 200(11):1639-43. DOI: 10.1086/646611. View

. Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites. PLoS Med. 2014; 11(7):e1001685. PMC: 4114488. DOI: 10.1371/journal.pmed.1001685. View

Alloueche A, Milligan P, Conway D, Pinder M, Bojang K, Doherty T . Protective efficacy of the RTS,S/AS02 Plasmodium falciparum malaria vaccine is not strain specific. Am J Trop Med Hyg. 2003; 68(1):97-101. View

10.

Lunn M, McNeil D . Applying Cox regression to competing risks. Biometrics. 1995; 51(2):524-32. View

11.

Lalvani A, Moris P, Voss G, Pathan A, Kester K, Brookes R . Potent induction of focused Th1-type cellular and humoral immune responses by RTS,S/SBAS2, a recombinant Plasmodium falciparum malaria vaccine. J Infect Dis. 1999; 180(5):1656-64. DOI: 10.1086/315074. View

12.

Gandhi K, Thera M, Coulibaly D, Traore K, Guindo A, Doumbo O . Next generation sequencing to detect variation in the Plasmodium falciparum circumsporozoite protein. Am J Trop Med Hyg. 2012; 86(5):775-81. PMC: 3335679. DOI: 10.4269/ajtmh.2012.11-0478. View

13.

Bailey J, Mvalo T, Aragam N, Weiser M, Congdon S, Kamwendo D . Use of massively parallel pyrosequencing to evaluate the diversity of and selection on Plasmodium falciparum csp T-cell epitopes in Lilongwe, Malawi. J Infect Dis. 2012; 206(4):580-7. PMC: 3491736. DOI: 10.1093/infdis/jis329. View

14.

Thera M, Doumbo O, Coulibaly D, Laurens M, Ouattara A, Kone A . A field trial to assess a blood-stage malaria vaccine. N Engl J Med. 2011; 365(11):1004-13. PMC: 3242358. DOI: 10.1056/NEJMoa1008115. View

15.

Sun P, Schwenk R, White K, Stoute J, Cohen J, Ballou W . Protective immunity induced with malaria vaccine, RTS,S, is linked to Plasmodium falciparum circumsporozoite protein-specific CD4+ and CD8+ T cells producing IFN-gamma. J Immunol. 2003; 171(12):6961-7. DOI: 10.4049/jimmunol.171.12.6961. View

16.

Campo J, Aponte J, Skinner J, Nakajima R, Molina D, Liang L . RTS,S vaccination is associated with serologic evidence of decreased exposure to Plasmodium falciparum liver- and blood-stage parasites. Mol Cell Proteomics. 2014; 14(3):519-31. PMC: 4349974. DOI: 10.1074/mcp.M114.044677. View

17.

Reece W, Pinder M, Gothard P, Milligan P, Bojang K, Doherty T . A CD4(+) T-cell immune response to a conserved epitope in the circumsporozoite protein correlates with protection from natural Plasmodium falciparum infection and disease. Nat Med. 2004; 10(4):406-10. DOI: 10.1038/nm1009. View

18.

Abdulla S, Oberholzer R, Juma O, Kubhoja S, Machera F, Membi C . Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants. N Engl J Med. 2008; 359(24):2533-44. DOI: 10.1056/NEJMoa0807773. View

19.

Esposito F, Lombardi S, Modiano D, Zavala F, Reeme J, Lamizana L . Prevalence and levels of antibodies to the circumsporozoite protein of Plasmodium falciparum in an endemic area and their relationship to resistance against malaria infection. Trans R Soc Trop Med Hyg. 1988; 82(6):827-32. DOI: 10.1016/0035-9203(88)90007-7. View

20.

Waitumbi J, Anyona S, Hunja C, Kifude C, Polhemus M, Walsh D . Impact of RTS,S/AS02(A) and RTS,S/AS01(B) on genotypes of P. falciparum in adults participating in a malaria vaccine clinical trial. PLoS One. 2009; 4(11):e7849. PMC: 2773849. DOI: 10.1371/journal.pone.0007849. View